Medx Health

What Medx Health does

MedX Health Corp. is a Canadian medical device and SaaS company, founded in 1999 and headquartered in Mississauga, Ontario, that develops proprietary SIAscopy (Spectrophotometric Intracutaneous Analysis) technology — a patented multispectral imaging method that non-invasively quantifies skin chromophores (collagen, melanin, and hemoglobin) at depths up to 2mm below the skin surface. Its product ecosystem comprises the SIAscope imaging device and HD Clinical Camera hardware pair, the DermSecure telemedicine platform (FDA-approved Software-as-a-Medical-Device enabling lesion capture and remote board-certified dermatologist review within 72 hours), the SkinSecure cloud-based SaaS platform (commercialized July 2026 for CRO clinical trial endpoints), and a portfolio of Class IIIb photobiomodulation laser systems (MedX Rehab Console/Portable/HOME, OraLase for dental, and LumaVet for veterinary applications). The company is publicly listed on the TSX Venture Exchange (MDX) and OTC (MDXHF), operates an ISO 13485-certified manufacturing facility, and holds regulatory clearances (FDA, Health Canada, CE, TGA, UK, Brazil) across 37-38 territories.

The business model combines device/hardware sales (SIAscope units priced at $4,000-$10,000) with a mix of recurring SaaS subscriptions (estimated ~$1,300/month per pharmacy partner on DermSecure; annual SkinSecure subscriptions for CROs) and per-scan transaction fees (approximately $20 to MedX of the ~$100 patient-paid scan at pharmacy partners). Distribution is multi-channel: direct enterprise sales and channel partners — PharmaChoice Canada (target 500-600 of 1,000+ independent pharmacies), Health Partners Group (UK/Ireland occupational health, 650+ corporate clients reaching 2M+ employees), 26+ CROs serving global beauty/personal-care brands, and regional distributors covering Italy, Turkey, and the UAE. The company is unprofitable and reported a 63% YoY revenue decline as of early 2026 while actively pivoting from a hardware/per-scan model toward multi-year recurring SaaS contracts, having been released from its prior exclusive SIAscopy licensing arrangement with Procter & Gamble in 2025 to enable direct licensing and partnership activity across skin health and aesthetics.

Name

Medx Health

Legal name

MedX Health Corp.

Website

https://medxhealth.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

MedX Health Corp. develops proprietary SIAscopy multispectral imaging devices and DermSecure/SkinSecure teledermatology platforms that enable non-invasive measurement of skin chromophores for clinical screening and CRO clinical trial endpoints.

Ownership category

akta.pro rank

Product category

Medical Imaging Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

General & Medical Dermatology (HLAKACAA)

akta.pro secondary industries

Laser & Energy-Based Dermatology (HLAKACAF), Dermocosmetics & Medical-Grade Skincare (CRABAAAF), Skincare Devices & Beauty Tech (LED, Microcurrent, Cleansing Devices) (CRABAAAJ)

Keywords

• Multispectral skin imaging
• Teledermatology platforms
• Photobiomodulation laser therapy
• Clinical trial biomarkers
• Non-invasive skin assessment

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Device/Hardware Sales: One-time sales of SIAscope devices and HD Camera sets to pharmacies, clinics, and occupational health providers. Prices range from $4,000 to $10,000 depending on configuration, generating estimated pretax margins of $2,000-$4,000 per unit.
2. DermSecure Platform Subscription: SaaS platform fees charged for access to the DermSecure telemedicine platform. Revenue model shifting from per-scan transaction fees to recurring subscription under multi-year contracts (3-year terms with Health Partners). Estimated ~$1,300 per month per adopting pharmacy.
3. SkinSecure Clinical Trial Platform: Subscription-based SaaS platform for CROs and sponsors conducting skin clinical trials. Annual platform costs significantly lower than traditional biopsy-based collagen measurement approaches. Targets dermatology, aesthetic, pharmaceutical, and consumer health sectors.
4. Photobiomodulation Laser Products: Sales of therapeutic laser devices including Rehab Console, Portable, HOME Unit, OraLase (dental), and LumaVet (veterinary). FDA-cleared products sold to clinics, hospitals, long-term care facilities, and dental practices.
5. Per-Scan Transaction Fees: Revenue per scan performed at pharmacy locations. Patient pays approximately $100 per scan, with approximately $20 remitted to MedX per scan under pharmacy partnership model.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

MedX Health develops and manufactures the patented SIAscope multispectral imaging device, which captures subsurface chromophore data (collagen, melanin, hemoglobin) up to 2mm below the skin surface, and offers it alongside the FDA-approved DermSecure teledermatology platform, the SkinSecure clinical trial SaaS platform, HD Clinical Camera, and Class IIIb photobiomodulation laser therapy systems. The integrated ecosystem serves dermatology clinics, occupational health providers, pharmacy chains, contract research organizations, and enterprise health programs with non-invasive, quantitative skin biomarker assessment.

Product overview

MedX Health operates as a data-driven skin health analytics business with a unified ecosystem comprising imaging devices, telemedicine software platforms, and photobiomodulation laser therapy systems. The core SIAscope device uses patented multispectral imaging technology to capture subsurface chromophore data (collagen, melanin, hemoglobin) up to 2mm depth, paired with an HD Clinical Camera for comprehensive lesion assessment. The DermSecure platform serves as the FDA-approved clinical assessment layer enabling secure transmission to dermatologists for remote evaluation. SkinSecure is the cloud-based SaaS platform for clinical trial and CRO applications, providing quantitative biomarker measurement as an alternative to invasive biopsies. The Photobiomodulation division offers Class IIIb laser systems (Rehab Console, Portable, HOME Unit, OraLase, LumaVet, OraLase Portable) for pain management, wound healing, and tissue repair across clinical, dental, and veterinary applications. All products are manufactured in MedX's ISO 13485-certified facility with regulatory clearance across 38 territories.

Differentiator

Problem solved

Functional benefit

Brands

• DermSecure: FDA-approved clinical assessment and detection platform for early skin cancer detection using teledermatology.
• SIAscope
• SkinSecure
• MedX Laser Therapy
• LumaVet
• Oralase
• MedX HOME Unit
• SIAMETRICS
• SIMSYS
• MoleMate

Products and services

• SIAscope Patented handheld multispectral imaging device that captures subsurface skin data by measuring key chromophores including melanin, hemoglobin, and collagen up to 2mm below the surface, producing detailed maps of lesion structure, pigmentation, and vascularity for dermatology assessment, occupational health screening, and clinical trial use.
• HD Clinical Camera High-resolution clinical imaging device that captures detailed visual context of skin lesions and produces Fitzpatrick skin type classification, used in conjunction with the SIAscope to correlate surface-level imaging with subsurface chromophore data.
• DermSecure FDA-approved clinical assessment and detection Software-as-a-Medical-Device that enables rapid, non-invasive lesion capture and secure transmission to board-certified dermatologists, with patient Electronic Health Records managed via HL7 FHIR interoperability.
• SkinSecure Cloud-based SaaS platform that links SIAscope imaging devices to clinical trial workflows, measuring sub-dermal changes in melanin, hemoglobin, and collagen up to 2mm below the surface to deliver evidence-based insight into treatment efficacy with audit-ready datasets for CROs and pharmaceutical/cosmetic sponsors.
• MedX Rehab Console Full-size, clinic-based Class IIIb photobiomodulation laser system for rehabilitation and physiotherapy settings, delivering consistent high-powered low-level laser therapy to larger treatment areas with touchscreen interface and preset/custom programs.
• MedX Rehab Portable Laser Compact, lightweight portable Class IIIb photobiomodulation device delivering the same low-level laser therapy as the console unit, designed for therapists requiring mobility between treatment rooms or off-site visits.
• MedX HOME Unit Consumer-focused Class IIIb photobiomodulation device that extends low-level laser therapy treatment beyond the clinic, allowing patients to continue care at home under healthcare provider guidance.
• OraLase / OraLase Portable Dental-specific Class IIIb low-level laser platform for in-office soft-tissue applications including inflammation reduction, pain relief after dental procedures, and faster healing, available in console and compact cordless portable versions.
• LumaVet Veterinary Class IIIb low-level laser therapy device for companion animals that helps reduce pain, swelling, and recovery times in pets with musculoskeletal or post-surgical conditions.

Quantifiable outcome

• Dermatologists reject only ~0.05% of images sent by MedX system (vs. 40%+ rejection rates for typical internet-transmitted images)
• +5 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered regional, core and minor.

• Vitamed BiomedicalregionalChannel Partner/ Reseller/ Distributor · 21 May 2025Commercial partner in Italy distributing MedX technology. Strategic collaboration with Medispa facilitates deployment across Italian pharmacies, medical centers, and wellness facilities. Represents key European growth market with aging population and increased skin cancer awareness.
• MedisparegionalChannel Partner/ Reseller/ Distributor · 21 May 2025Leading Italian healthcare company delivering innovative digital solutions for prevention, wellness, and healthcare. Partnership with MedX and Vitamed Biomedical deploys SIAscope on DermSecure platform across Medispa's extensive network of pharmacies, medical centers, and wellness facilities.
• Health Partners Group LtdcoreChannel Partner/ Reseller/ Distributor · 15 May 2025UK's largest occupational health services provider signed commercial agreement following successful pilot. Deployment across UK and Republic of Ireland targeting 2 million+ employees through 650+ corporate clients. Addresses occupational health market for workplace skin cancer screening with 11% of pilot participants requiring dermatological follow-up.
• PharmaChoice CanadacoreChannel Partner/ Reseller/ Distributor · 18 April 2023Partnership with Canada's fastest-growing pharmacy group (1,000+ independent pharmacies) to deploy SIAscope and DermSecure platform. Pilot launched May 2023 at 20 locations in 4 provinces, expanding to 500-600 locations. Provides pharmacy customers access to dermatologist assessment within 72 hours.
• Makromed/Arhan Global A.ŞregionalChannel Partner/ Reseller/ Distributor · 12 May 2022Distribution agreement for launch of MedX teledermatology screening platform in Turkey. Enables market expansion into Turkey with regulatory approvals in place.
• Al Zahrawi Medical Supplies LLCregionalChannel Partner/ Reseller/ Distributor · 18 November 2021Distribution agreement for teledermatology screening platform in United Arab Emirates. Supports Middle East market expansion.
• London Medical Laboratory LtdregionalChannel Partner/ Reseller/ Distributor · 27 September 2021Commercialization pilot of world-class teledermatology screening platform in the United Kingdom initiated November 2021.
• VidaCeuticals Health Products Inc.minorChannel Partner/ Reseller/ Distributor · 15 June 2021North American distribution partnership for MedX health products.
• Empower Clinics Inc.minorChannel Partner/ Reseller/ Distributor · 10 March 2021Pilot program for MedX teledermatology screening platform at Select Ontario Integrated Health Centres.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Canfield Scientific: A leading US-based provider of dermatology imaging systems, total body photography, and clinical image management software used by dermatologists, plastic surgeons, and aesthetic practices. Directly comparable to MedX in delivering specialized imaging hardware and software to dermatology clinics and clinical research customers.
• FotoFinder Systems: German developer of AI-enabled dermatoscopy, total body mapping, and skin cancer screening systems sold to dermatologists and clinics worldwide. Comparable to MedX in offering hardware-plus-software skin imaging platforms with regulatory clearances across multiple geographies.
• DermLite (3Gen): US-based manufacturer of dermatoscopes and digital skin imaging devices widely used by dermatologists and primary care for skin lesion evaluation. Comparable to MedX in serving the same skin-cancer-detection clinical workflow with portable, FDA-cleared imaging hardware.
• MetaOptima Technology: Canadian developer of the DermEngine dermatology imaging and AI platform, including total body photography and teledermatology modules. Directly comparable to MedX as a Vancouver-area dermatology imaging software and AI company serving clinicians and enterprises.
• Caliber Imaging & Diagnostics (Vivosight): US-listed developer of confocal microscopy and multispectral imaging systems used in dermatology research and clinical applications. Comparable to MedX in providing advanced optical skin imaging technology for dermatology research and clinical decision support.
• LiteCure Medical: US-based manufacturer of Class IV photobiomodulation/laser therapy devices sold to veterinarians, chiropractors, physical therapists, and dental clinics. Comparable to MedX's LumaVet, OraLase, and Rehab Console product family in the PBM laser segment for pain management and tissue repair.

Emerging players

• SkinVision: Amsterdam-based AI skin cancer detection app that uses smartphone cameras to assess lesion risk. Comparable to MedX's DermSecure in the consumer-accessible skin cancer triage space, but via a smartphone-first rather than dedicated hardware approach.
• Skin Analytics: UK-based AI dermatology platform with NHS and private clinic deployments for automated skin lesion assessment. Comparable to MedX's DermSecure in UK teledermatology pathways and in selling to occupational health and primary care for earlier skin cancer triage.
• Verisante Technology: Canadian developer of the Aura and Core skin cancer detection devices using Raman spectroscopy. Comparable to MedX as a smaller Canadian-listed skin imaging device maker focused on non-invasive lesion assessment for dermatologists.
• Michelson Diagnostics: UK-based developer of multi-beam optical coherence tomography (OCT) skin imaging for dermatology research and clinical use. Comparable to MedX in offering advanced optical skin imaging hardware for dermatology with a UK regulatory footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights6 records

Customer concentration

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds9 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medx Health